Application of RhCcEe compatible blood transfusion in patients with repeated blood transfusion
Objective:To investigate the application of RhCcEe compatible blood transfusion in patients with repeated blood transfusion.Methods:Sixty-six patients who received repeated blood transfusion in the hospital from January 2022 to June 2023 were selected as the research subjects.Using the random number table,they were assigned to the control group(33 cases)and the experimental group(33 cases),receiving conventional blood transfusion(matching ABO and RhD blood types)and RhCcEe compatible blood transfusion,respectively.The production of new antibodies and changes in blood indicators[red blood cell count(RBC)and hemoglobin level(Hb)]in the two groups were observed.The expected increase in Hb and the incidence of adverse reactions to transfusion were calculated.Results:The production rate of new antibodies in the experimental group was lower than that in the control group(P<0.05).Only one case in the experimental group did not achieve the expected Hb value after red blood cell transfusion.Nine cases in the control group did not achieve the expected Hb value after multiple red blood cell transfusion,and five cases even showed a decrease in Hb after transfusion.The ineffective transfusion rate in the experimental group(3.03%)was much lower than that in the control group(42.42%)(x2=14.580,P<0.05).The levels of RBC and Hb in the experimental group were higher than those in the control group after transfusion.The experimental group had fewer adverse reactions than the control group(P<0.05).Conclusion:RhCcEe compatible blood transfusion can reduce the production rate of new antibodies,improve blood indicators,and reduce the occurrence of adverse reactions in patients with repeated blood transfusion.
NETL
NSTL
万方数据
